AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.

The entities involved

• AbbVie →

  pharmaceutical company

  • AbbVie announced a joint development partnership with IGI, led by Lida Pacaud.Wed 17:17
  • Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.Wed 16:42
• Eli Lilly and Company →

  American pharmaceutical company

  • Nvidia is a top holding in VOO, which also holds Apple Inc. as a major position. Warren Buffett advises investing in S&P 500 ETFs, noting Eli Lilly as a key non-tech giant.Wed 21:56
  • Trade data and legislative control are currently influencing market sentiment and corporate operations.Wed 14:24
• Merck →

  public company in Indonesia

  • Merck forged a strategic alliance with R-Pharm on November 1, 2026.Mon 06:38
  • AstraZeneca formed a partnership with Daiichi Sankyo regarding Enhertu, and also established a profit-sharing deal with Merck for Lynparza.Sun 14:45

Related events

• AbbVie and Abbott Laboratories are large healthcare companies whose corporate histories are linked by a major split that occurred in 2013.Jun 7
• Eli Lilly and Company and BeOne Medicines Ltd. are both identified as major players in the medical sector.Oct 16
• AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.Jun 22
• Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.Oct 21
• Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.Aug 5